Poolbeg Pharma PLC SAB Endorses Influenza Drug Targets
26 Outubro 2023 - 3:00AM
RNS Non-Regulatory
TIDMPOLB
Poolbeg Pharma PLC
26 October 2023
Poolbeg Pharma plc
Scientific Advisory Board Endorses Influenza Drug Targets
Identified in AI Drug Discovery Programme
Consensus reached on prioritised novel drug targets to bring
forward for lab-based validation
26 October 2023 - (AIM: POLB, O TCQB: POLBF, 'Poolbeg' or the
'Company'), a clinical-stage biopharmaceutical company targeting
diseases with a high unmet medical need, announces that its
Scientific Advisory Board ('SAB') has endorsed the influenza drug
targets identified in its AI-led drug discovery programme.
Key highlights
-- Prioritisation of influenza drug targets which have the highest likelihood of success
-- New potential collaborative routes to maximise the impact of the outputs identified
-- Ongoing discussions with prospective partners on these novel
and exciting targets discovered using AI
The SAB was presented with comprehensive data and information
regarding the large number of novel drug targets identified as part
of the CytoReason collaboration in June 2023, along with a proposed
list of prioritised candidates. Prioritisation was based on several
key criteria and an evaluation by both Poolbeg and CytoReason's
teams of expert biologists and data scientists to identify the
top-ranking genes potentially suitable for the treatment of
influenza.
The members of the SAB considered the data and were impressed
with the outputs of the programme, a consensus was reached on the
prioritised list of novel drug targets to bring forward for
lab-based validation, which is expected to complete in 2024. They
also provided valuable insight into how to most effectively
validate the targets in line with Poolbeg's model.
The global interest in AI-led drug discovery continues to grow,
with Big Pharma investing heavily in the space. This approach to
drug discovery enables identification of targets faster, at lower
cost, with reduced risk, and a higher likelihood of success. The
Company continues to discuss the exciting outputs from its AI-led
drug discovery programmes with prospective partners.
Prof Luke O'Neill, SAB Chair and Professor of Biochemistry in
the School of Biochemistry and Immunology, Trinity Biomedical
Sciences Institute at Trinity College Dublin said, "I am excited by
the potential of these novel drug targets generated in Poolbeg's
AI-led drug discovery programme. Global focus on AI-led drug
discovery continues to grow and Poolbeg is leading the way due to
the uniqueness and the quality of the data incorporated into its
programme which has unveiled unparalleled insights into human
disease."
Prof Brendan Buckley, SAB Member and Honorary Clinical Professor
at University College Cork and University College Dublin said:
"Influenza is a disease which affects millions each year and there
remains a significant unmet need for effective treatments. By
targeting specific genes which are involved in influenza disease
progression and severity, this approach could transform the
treatment of this infectious disease for both seasonal and pandemic
strains."
Jeremy Skillington, PhD, Chief Executive Officer of Poolbeg
Pharma, said: "The endorsement of these prioritised targets
generated from our AI-led drug discovery programme by the
Scientific Advisory Board validates our approach and strategy going
forward. We are committed to improving the world's access to
critically needed treatments, and we believe our use of such
innovative technology will play a pivotal role in advancing
healthcare solutions."
- Ends -
Enquiries
Poolbeg Pharma Plc
Jeremy Skillington, CEO
Ian O'Connell, CFO +44 (0) 207 183 1499
Cavendish Capital Markets Ltd (Nominated
Adviser & Joint Broker)
Geoff Nash, Charlie Beeson, Nigel
Birks, Harriet Ward (ECM) +44 (0) 207 220 0500
Singer Capital Markets (Joint Broker)
Phil Davies, Sam Butcher +44 (0) 207 496 3000
J&E Davy (Joint Broker)
Anthony Farrell, Niall Gilchrist +353 (0) 1 679 6363
Optimum Strategic Communications +44 (0) 208 078 4357
Nick Bastin, Hana Malik, Vici Rabbetts poolbeg@optimumcomms.com
About Poolbeg Pharma
Poolbeg Pharma specialises in the development of innovative
medicines to address the unmet need in infectious and other
prevalent diseases. Poolbeg Pharma has a disciplined portfolio
approach to mitigate risk, accelerate drug development, and enhance
investor returns. The Company simultaneously advances multiple
programmes in cost-effective clinical trials, rapidly generating
early human safety and efficacy data to enable early partnering /
out-licensing, with the funds generated reinvested in the pipeline.
Poolbeg Pharma also uses AI to interrogate human challenge trial
data sets to quickly identify new targets and drugs, leading to
faster development and greater commercial appeal.
The Company is targeting the growing infectious disease market.
In the wake of the COVID-19 pandemic, infectious disease has become
one of the fastest growing pharma markets and is expected to exceed
$250bn by 2025. Through opportunistic identification of assets
which complement Poolbeg Pharma's existing pipeline, the Company is
progressing programmes in oncology and metabolic syndromes; adding
disease areas with significant addressable markets.
With its initial assets from hVIVO plc , an industry leading
infectious disease and human challenge trials business, Poolbeg
Pharma has access to knowledge, experience, and clinical data from
over 20 years of human challenge trials. The Company is using these
insights to acquire new assets as well as reposition clinical stage
products, reducing spend and risk. Amongst its portfolio of
exciting assets, Poolbeg Pharma has a small molecule
immunomodulator for severe influenza and other acute inflammatory
conditions (POLB 001) which produces a highly significant reduction
in p38 MAP kinase driven cytokines in a clinical setting; a
first-in-class, intranasally administered RNA-based immunotherapy
for respiratory virus infections (POLB 002); and a vaccine
candidate for Melioidosis (POLB 003). The Company is progressing
two A rtificial I ntelligence (AI) P rogrammes to add promising new
assets to its pipeline as well as developing an Oral Vaccine
Programme and utilising its licensed Oral Delivery Platform to
target metabolic conditions.
For more information, please go to www.poolbegpharma.com or
follow us on Twitter and LinkedIn @PoolbegPharma.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAFESFMIEDSEIS
(END) Dow Jones Newswires
October 26, 2023 02:00 ET (06:00 GMT)
Poolbeg Pharma (LSE:POLB)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Poolbeg Pharma (LSE:POLB)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024
